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Objective: To evaluate the efficacy and safety of three doses of ciclesonide (with or without
spacer) in children with persistent asthma.
Patients and methods: This was a multicentre, double-blind, placebo-controlled, 12-week
study of ciclesonide 40, 80 or 160 mg (once daily pm). Children (6e11 years) were randomised
1:1 to treatment via a metered dose inhaler (MDI) or MDI plus spacer. The primary variable was
change from baseline in mean morning peak expiratory flow (PEF). Secondary variables
included: time to first lack of efficacy (LOE), asthma control, forced expiratory volume in
1 s (FEV1), asthma symptom score and quality of life (QoL). Safety assessments included:
adverse events (AEs), urinary cortisol excretion and body height.
Results: In total, 1073 children received treatment. At endpoint, mean morning PEF signif-
icantly improved with all doses of ciclesonide vs. placebo. There was no difference over
placebo in time to first LOE, but ciclesonide was superior to placebo on asthma control,
symptom score, FEV1 and QoL. There were no differences between the spacer or non-search Unit, Kolding Hospital, University of Southern Denmark, DK-6000 Kolding, Denmark. Tel.: þ45
(S. Pedersen).
0 Elsevier Ltd. All rights reserved.
Ciclesonide for childhood asthma: The RAINBOW study 1619spacer subgroups. The incidences of AEs were comparable between treatment groups
(approximately 35%) and there were no between-group differences in body height or
urinary cortisol.
Conclusions: Ciclesonide 40e160 mg once daily is effective and well tolerated in children
with persistent asthma; its efficacy and safety are unaffected by the use of a spacer.
clinicaltrials.gov registration number: NCT00384189.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Childhood asthma causes considerable morbidity worldwide
and is the most prevalent chronic disease in children.1
Global Initiative for Asthma (GINA) guidelines recommend
inhaled corticosteroid (ICS) monotherapy as first-line
treatment for patients older than 5 years.2 The latest
guidelines from the National Heart, Lung, and Blood Insti-
tute reinforce this, specifying that ICSs are the most potent
and consistently effective long-term control medication for
asthma in children.3 These recommendations are based on
extensive data from randomised trials in children, which
demonstrate that ICSs significantly improve asthma symp-
toms, increase asthma-free days, reduce the need for
rescue medication, improve lung function, and reduce
exacerbations versus placebo, and improve measures of
impairment and risk to a greater extent than non-steroidal
anti-inflammatory medication.4 ICSs are also generally well
tolerated.4 Nevertheless, concerns about long-term
suppression of the hypothalamic-pituitary-adrenal (HPA)
axis and an initial reduction in growth rates, which have
been reported in many studies, persist;5 consequently,
some clinicians prefer not to use ICSs as first-line therapy.6
Ciclesonide is an ICS pro-drug that is converted to its
active form, desisobutyryl-ciclesonide, by esterases in the
airways.7 The efficacy and safety of ciclesonide has been
widely demonstrated in children with asthma,8e11 but few
studies have assessed the doseeresponse relationships of
several doses of the drug.
The RAINBOW study assessed the doseeresponse rela-
tionship with three doses of ciclesonide (40, 80 and 160 mg)
given once daily in the evening in children with asthma. As
some children are unable to use a metered dose inhaler
(MDI) effectively, a secondary objective was to examine the
impact of spacer use on the efficacy and safety of
ciclesonide.Methods
Study design and treatments
This was a double-blind, randomised, parallel-group study
performed in 110 sites in Bulgaria, Germany, Hungary,
Poland, Romania, Russia, South Africa, Spain and Ukraine.
The study consisted of a run-in period (2e4 weeks) and
a 12-week treatment period. At the start of the run-in
(baseline) period, eligible patients discontinued their
previous asthma medications and received a placebo MDI
to practice their inhalation technique (one puff in the
evening). The duration of the run-in period was sufficientto ensure washout of any previous ICSs.12 Patients were
then randomised into one of four treatment groups in
a 2:2:2:1 ratio (ciclesonide 40 mg: ciclesonide 80 mg:
ciclesonide 160 mg: placebo) by means of a computer-
generated randomisation scheme. In addition, patients
were randomly allocated (1:1) to inhale the study medi-
cation either with or without a spacer device (Aero-
Chamber Plus, Trudell Medical International, Ontario,
Canada).
During the treatment period, patients inhaled one puff
(40, 80 or 160 mg) of ciclesonide (ex-actuator; equivalent to
50, 100 and 200 mg ex-valve) or one puff of placebo in the
evening. All treatments were administered via MDIs of
identical appearance using hydrofluoroalkane134a (HFA-
134a) as the propellant. Salbutamol (100 mg/puff) was
provided as rescue medication throughout the study; no
other asthma medication was permitted. Patients visited
the study sites weekly during the run-in (baseline) period
and bi-weekly during the treatment period.
The study was conducted in accordance with Good
Clinical Practice and the ethical principles of the Declara-
tion of Helsinki. Written consent was obtained from the
patients’ parent(s) or legal guardian(s), and the protocol
was approved by the appropriate Independent Ethics
Committee or Institutional Review Boards.
Patients
Male and female outpatients aged 6e11 years with a history
of persistent bronchial asthma13 for 6 months were
eligible for participation. Patients also had to be able to
perform reproducible lung function tests and have an
acceptable MDI inhalation technique. In the 30 days prior to
study entry, patients could be treated with: rescue medi-
cation only; a constant dose of fluticasone propionate
200 mg/day or equivalent; or other controller medica-
tions. Randomisation criteria at the end of the run-in period
included a mean peak expiratory flow (PEF) value (over last
week) of 40e90% of the predicted value, as well as forced
expiratory volume in 1 s (FEV1) reversibility of 12% pre-
dicted after inhalation of 200e400 mg salbutamol. In addi-
tion, patients had to present asthma symptoms on at least 6
of the last 10 days of the baseline period, or use of at least
eight puffs of rescue medication within the last 10 days of
the baseline period.
Exclusion criteria included a history of near fatal
asthma; a respiratory tract infection or asthma exacerba-
tion within the last 30 days; two or more in-patient hospi-
talisations for asthma in the previous year; use of systemic
glucocorticosteroids within 30 days prior to study entry or
for >60 days in the previous 2 years.
1620 S. Pedersen et al.Efficacy assessments
The highest of three daily morning and evening PEF
measurements, performed with an electronic peak flow
meter (AM2þ, VIASYS Healthcare GmbH, Hoechberg,
Germany), was recorded in a diary, together with the use of
rescue medication and daytime and night-time asthma
symptoms, which were scored from 0 to 4 (0 equalled no
asthma symptoms; 4 represented being awake most of the
night or being unable to carry out daytime activities
because of asthma).
Spirometry measurements (FEV1 and PEF) were per-
formed according to international guidelines at each clinic
visit.14,15 Percent-predicted values were calculated as
previously described.16
The patients’ quality of life was assessed at the start and
the end of the treatment period by using the standardised
paediatric asthma quality of life questionnaire (PAQLQ[S]).17
Treatment compliance was not formally monitored;
however, patients and/or caregivers were told to report
deviations from the intended treatment schedule in the
diaries.
Primary and secondary efficacy variables
The primary variable was change in mean morning PEF
(average over last week).
Key secondary variables were time (in days) to first loss
of efficacy (LOE) and the percentage of days with asthma
control. LOE was defined as worsening of asthma symptoms
requiring a change in the patient’s medication, other than
rescue medication. Additional LOE criteria included:
nocturnal awakenings, use of eight or more puffs of rescue
medication, and decrease in morning PEF to <80% of the
baseline value on 4 consecutive days.
Patients who fulfilled the LOE criteria were withdrawn
and treated according to individual needs. Two differentTable 1 Baseline demographics (ITT population).
CIC 40 mg
(nZ 305)
Age, years Median (range) 8.0 (6e11)
Height, cm Mean (SD) 134.6 (10.8)
Sex, n (%) Male 210 (68.9)
Race, n (%) Caucasian 276 (90.5)
Duration of asthma, months Median (range) 41.4 (6e127)
ICS pre-treatment, n (%) Yes 200 (65.6)
Dose, mg (BDP equivalents) Mean (SD) 323.2 (120.0)
Asthma control according
to GINA, n (%)
Controlled 4 (1.3)
Partly controlled 107 (35.1)
Uncontrolled 158 (51.8)
Asthma symptom score/day Median (range) 1.57 (0.00e4.8
FEV1, % predicted Mean (SD) 82.2 (13.7)
Rescue medication, puffs/day Median (range) 1.43 (0.00e7.8
Asthma control days, % Median (range) 0.00 (0.00e63.
PAQLQ(S) overall score Mean (SD) 5.43 (1.22)
BDP, beclomethasone dipropionate; CIC, ciclesonide; FEV1, forced e
inhaled corticosteroid; ITT, intent-to-treat; PAQLQ(S), standardised
deviation.definitions of asthma control were evaluated: a day without
asthma symptoms and without use of rescue medication,
and a day without asthma symptoms, without use of rescue
medication, with a morning PEF >80% predicted and with
PEF fluctuation <15%.
Other efficacy variables included changes in: asthma
symptom scores; asthma control defined on the basis of
asthma symptoms and rescue medication; and PAQLQ(S)
scores.
Safety and tolerability assessments
Adverse events (AEs) were assessed at each study visit by
open questioning. Their nature, incidence, intensity and
investigator’s causality assessment were recorded. Physical
examinations (including vital signs and laboratory tests)
were performed at screening and at Week 12. Twenty-four-
hour urine samples for analysis of free urinary cortisol and
creatinine were collected at baseline and at the end of
treatment. At investigational sites where a stadiometer was
available, height was also measured at the start and end of
the treatment period. Stadiometry is widely acknowledged
as the most reliable means of measuring height and is
recommended by the Food and Drug Administration (FDA)
for studies assessing growth.18
Statistical analyses
The sample size of 1050 randomised patients (ciclesonide
dose groups nZ 300 each; placebo nZ 150) was chosen to
confirm superiority of ciclesonide 160 mg vs. placebo on the
primary variable with 96% power. Similar power consider-
ations were done for the other variables and pair-wise
comparisons. Analyses of the efficacy variables were per-
formed on a confirmatory basis and in hierarchical order, to
assess superiority over placebo. To assess superiority of
ciclesonide over placebo, the superiority of ciclesonideCIC 80 mg
(nZ 312)
CIC 160 mg
(nZ 310)
Placebo
(nZ 146)
8.0 (6e11) 9.0 (6e11) 8.0 (6e11)
134.5 (11.0) 135.9 (10.8) 134.6 (11.1)
191 (61.2) 218 (70.3) 92 (63.0)
279 (89.4) 277 (89.4) 133 (91.1)
41.9 (5e128) 41.7 (6e129) 47.1 (6e122)
204 (65.4) 199 (64.2) 102 (69.9)
340.7 (119.3) 319.3 (110.7) 321.5 (120.3)
7 (2.2) 3 (1.0) 0 (0)
102 (32.7) 98 (31.6) 53 (36.3)
166 (53.2) 163 (52.6) 73 (50.0)
8) 1.71 (0.00e5.14) 1.57 (0.00e4.63) 1.71 (0.00e5.14)
81.5 (13.7) 81.9 (13.8) 81.7 (14.1)
6) 1.43 (0.00e7.14) 1.57 (0.00e7.71) 1.43 (0.00e7.43)
6) 0.00 (0.00e100.0) 0.00 (0.00e60.0) 0.00 (0.00e46.2)
5.36 (1.12) 5.42 (1.10) 5.30 (1.11)
xpiratory volume in 1 s; GINA, Global Initiative for Asthma; ICS,
paediatric asthma quality of life questionnaire; SD, standard
aOne patient was randomised to CIC 160 mg, but received CIC 40 mg.
CIC, ciclesonide. 
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Figure 1 CONSORT diagram (patient disposition).
Ciclesonide for childhood asthma: The RAINBOW study 1621160 mg vs. placebo in morning PEF was tested first (2.5%
significance level, one-sided). Only if superiority was
shown, the superiority test for ciclesonide 80 mg vs. placebo
was performed. If the superiority of ciclesonide 80 mg was
demonstrated, the key secondary variables were subjected
to the confirmatory testing procedure in hierarchical order;
otherwise, all subsequent analyses were considered
exploratory. Details of other statistical tests are given in
the online Supplementary material.0
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Figure 2 Change (LS mean [SEM]) in morning PEF (L/min).All analyses were performed on the intent-to-treat (ITT)
population, which included all randomised patients who took
at least one dose of study medication. For patients who
discontinued treatment before Week 12, missing values were
analysed using a last observation carried forward (LOCF)
approach. To confirm the robustness of the ITT efficacy
results, a per-protocol (PP) analysis was also performed and
interpreted as a supportive analysis; only the results for the
ITT analysis are reported. A restricted safety analysis was
performed for urinary cortisol and body height data, in
patients with valid measurements (e.g. those with corre-
sponding creatinine values within the reference range and
all measurements taken by the same device, respectively).
Results
Patients
In total, 1080 patients were randomised to treatment with
ciclesonide 40 mg (n Z 304), ciclesonide 80 mg (n Z 312),
ciclesonide 160 mg (n Z 313) or placebo (n Z 150). Of
these, 1073 received study medication and comprised the
ITT population.
Baseline demographics were similar across the treat-
ment groups (Table 1). Mean age was 8.4 years and most
children (n Z 920) had either partly controlled or uncon-
trolled asthma at baseline. Patient disposition is shown in
Fig. 1. The number of withdrawals was slightly higher in the
placebo group (24.7%) vs. the ciclesonide treatment groups
Table 2 Changes from baseline in efficacy variables, within-treatment differences and differences between active drug and
placebo (ITT population).
Within-treatment difference p-valuea Between treatment difference 95% CI p-value vs. placebob
LS mean change in morning PEF, L/min (SEM)
CIC 40 mg 15.2 (2.7) <0.001 9.8 (4.3) 1.4, 18.3 0.012
CIC 80 mg 14.8 (2.6) <0.001 9.4 (4.3) 0.9, 17.8 0.015
CIC 160 mg 17.4 (2.7) <0.001 12.0 (4.3) 3.5, 20.4 0.003
Placebo 5.4 (3.7) 0.1459 e e e
Percentage of days with asthma control, % of days (HL point estimate)
CIC 40 mg 16.86 <0.001 0.00 0.00, 5.26 0.001
CIC 80 mg 16.43 <0.001 0.00 0.00, 5.56 0.0006
CIC 160 mg 21.15 <0.001 0.25 0.00, 5.56 0.0002
Placebo 5.00 <0.001 e e e
LS mean change in FEV1, L (SEM)
CIC 40 mg 0.123 (0.015) <0.001 0.084 (0.025) 0.035, 0.133 <0.001
CIC 80 mg 0.122 (0.015) <0.001 0.083 (0.025) 0.034, 0.132 <0.001
CIC 160 mg 0.139 (0.015) <0.001 0.100 (0.025) 0.050, 0.149 <0.001
Placebo 0.039 (0.022) 0.0709 e e e
Change in asthma symptom score, points/day (HL point estimate)
CIC 40 mg 1.00 <0.001 0.33 0.58, 0.10 <0.01
CIC 80 mg 1.05 <0.001 0.41 0.62, 0.14 <0.01
CIC 160 mg 0.95 <0.001 0.29 0.57, 0.05 <0.01
Placebo 0.64 <0.001 e e e
Change in use of rescue medication, puffs/day (HL point estimate)
CIC 40 mg 0.93 <0.001 0.19 0.48, 0.00 0.048
CIC 80 mg 1.00 <0.001 0.29 0.57, 0.05 <0.01
CIC 160 mg 0.95 <0.001 0.29 0.57, 0.00 <0.025
Placebo 0.64 <0.001 e e e
Change in PAQLQ(S) overall score, LS mean (SEM)
CIC 40 mg 0.78 (0.07) <0.001 0.35 (0.11) 0.12, 0.57 <0.01
CIC 80 mg 0.71 (0.07) <0.001 0.28 (0.11) 0.05, 0.50 <0.01
CIC 160 mg 0.72 (0.07) <0.001 0.28 (0.11) 0.06, 0.51 <0.01
Placebo 0.43 (0.10) <0.001 e e e
a Two-sided p-value, significance level 5.0%.
b One-sided p-value, significance level 2.5%. CI, confidence interval; CIC, ciclesonide; FEV1, forced expiratory volume in 1 s; HL,
HodgeseLehmann; ITT, intent-to-treat; LS, least squares; PAQLQ(S), standardised paediatric asthma quality of life questionnaire; PEF,
peak expiratory flow; SEM, standard error of the LS mean.
1622 S. Pedersen et al.(ciclesonide 40 mg: 16.4%; ciclesonide 80 mg: 18.3%; cicle-
sonide 160 mg: 17.7%). The main reason for withdrawal from
the study was LOE (ciclesonide 40 mg, 14.8%; ciclesonide
80 mg, 15.4%; ciclesonide 160 mg, 16.1%; placebo, 21.9%).Efficacy
Significant increases from baseline to week 12 in mean
morning pre-bronchodilator diary PEF (L/min) were seen
with all doses of ciclesonide, but not with placebo (ITT
analysis, Fig. 2). All doses of ciclesonide were superior to
placebo (p Z 0.012 for 40 mg; p Z 0.015 for 80 mg;
p Z 0.003 for 160 mg) (Table 2).
At week 12, there were no significant differences
between any of the ciclesonide doses and placebo in the
time to first LOE. The probability of not experiencing LOE
(KaplaneMeier estimate) vs. placebo was: 72.8 (p Z 0.14)
for ciclesonide 40 mg; 74.5 (pZ 0.09) for ciclesonide 80 mgand 73.2 (pZ 0.16) for ciclesonide 160 mg. In all treatment
groups, the most frequent reasons for LOE were nocturnal
awakenings and a decrease in morning PEF to <80% of the
baseline value on 4 consecutive days.
The percentage of asthma control days (defined as days
without symptoms and rescue medication) was approxi-
mately 15% at baseline, increasing to 58.1% in the placebo
group and to approximately 80% in all ciclesonide groups
(Fig. 3A). The corresponding proportions of patients with an
increase in the percentage of asthma control days were:
45.2% (ciclesonide 40 mg), 44.8% (ciclesonide 80 mg), 45.8%
(ciclesonide 160 mg) and 32.6% (placebo); all treatment
differences vs. placebo were statistically significant
(p Z 0.0013, p Z 0.0014 and p Z 0.0006, respectively).
Data on the percentage of days with asthma control
during treatment in patients whose asthma was partly
controlled and uncontrolled at baseline are shown in Fig. 3B
and C, respectively. A significant doseeresponse with
ciclesonide was seen in patients whose asthma was
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Figure 3 Change from baseline in the percentage of asthma
control days (defined on the basis of asthma symptoms and
rescue medication use) according to patients’ asthma control
(GINA criteria13) at baseline. A statistically significant dos-
eeresponse was seen in patients with uncontrolled asthma at
baseline (p Z 0.044).
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Figure 4 Change from baseline in the percentage of asthma
control days (defined on the basis of asthma symptoms, rescue
medication use, morning PEF and PEF fluctuation) according to
patients’ asthma control (GINA criteria13) at baseline. A
statistically significant doseeresponse was seen in patients
with uncontrolled asthma at baseline (p Z 0.0002).
Ciclesonide for childhood asthma: The RAINBOW study 1623uncontrolled at baseline (p Z 0.044); no doseeresponse
effect was obvious in patients with partially controlled
asthma at baseline.
When using a more stringent definition of asthma control
(days without symptoms and rescue medication, morning
PEF >80% predicted and PEF fluctuation <15%), the
improvements seen in all treatment groups were smaller
(Fig. 4A). The proportions of patients who had an
improvement in the percentage of asthma control days
were: 52.6% (ciclesonide 40 mg), 53.5% (ciclesonide 80 mg),
53.7% (ciclesonide 160 mg) and 39.7% (placebo); all treat-
ment differences vs. placebo were statistically significant
(p Z 0.002, p Z 0.0006 and p Z 0.001, respectively). No
doseeresponse was seen in patients with partly controlled
asthma at baseline (Fig. 4B), whereas a highly significant
doseeresponse was noted in patients with previously
uncontrolled asthma (p Z 0.0002) (Fig. 4C).All doses of ciclesonide showed significant improvements
vs. placebo for FEV1 (Table 2). Significant improvements vs.
placebo were also seen for asthma symptoms (all cicleso-
nide doses) and rescue medication (ciclesonide 80 and
160 mg) (Table 2).
Quality of life
PAQLQ(S) scores were significantly improved from baseline
to week 12 in all treatment groups, including placebo. All
doses of ciclesonide significantly improved quality of life
compared with placebo (Table 2).
Safety and tolerability
Adverse events
The incidence of treatment-emergent AEs was comparable
in all treatment groups (ciclesonide 40 mg, 37.4%; 80 mg,
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Comparisons between CIC (all doses) and placebo were non-significant (p > 0.05);
p < 0.0001 vs. baseline for all treatments.
Error bars are ± 1 SEM.
CI, confidence interval; CIC, ciclesonide; LS, least squares; SEM, standard error of the LS mean.
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Figure 5 Change from baseline in A) urinary cortisol adjusted for creatinine (HL point estimate, restricted safety analysis) and B)
body height measured by stadiometry (restricted safety analysis) for the total population and spacer subgroups.
1624 S. Pedersen et al.35.6%; 160 mg, 32.9%; placebo, 32.9%); most AEs were mild
or moderate in severity.
The most frequently reported AEs were upper respira-
tory tract infections (ciclesonide 40 mg, 5.9%; 80 mg, 6.4%;
160 mg, 5.2%; placebo, 3.4%) and pharyngitis (ciclesonide
40 mg, 4.6%; 80 mg, 5.8%; 160 mg, 5.2%; placebo, 4.8%). In
total, 14 patients withdrew due to AEs, as follows: asthma
(n Z 4), bronchitis (n Z 1), sinusitis (n Z 3), wheezing
(nZ 2), pyrexia (nZ 1), rhinitis (nZ 1), upper respiratory
tract infection (nZ 1) and lower respiratory tract infection
(n Z 1). Overall, the incidence of AEs considered to be
related to study medication was very low (0.7%). The total
incidence of serious AEs was also low (1.1%) and compa-
rable between all treatment groups; none were considered
to be related to study medication and there were no deaths
during the study. AEs of interest are listed in the online
Supplementary material.
HPA-axis function and body height
At study end, there were no statistically significant changes
from baseline in urinary cortisol levels (adjusted for
creatinine) between ciclesonide and placebo (Fig. 5a).Body height significantly increased from baseline in all
treatment groups (p < 0.0001) (Fig. 5b). There were no
significant differences in growth rate between any of the
doses of ciclesonide and placebo (p > 0.05).
Impact of spacer use
No differences were observed between the spacer and non-
spacer subgroups for any of the efficacy or safety outcomes
(Table 3; Fig. 5a and b).Discussion
The main findings in the present study were that: 1) low
daily doses of ciclesonide were clinically significantly more
effective than placebo for the vast majority of outcomes;
2) clinically effective doses were without any detectable
adverse systemic effects; 3) no apparent doseeresponse
relationship was demonstrated in the overall population,
but significant doseeresponse relationships were seen for
the two definitions of asthma control in patients with
uncontrolled asthma at baseline; and 4) use of a spacer did
Table 3 Change from baseline in efficacy variables for spacer and non-spacer groups (endpoint analysis; ITT population
CIC 40 mg CIC 80 mg CIC 160 mg Placebo
Spacer No spacer Spacer No spacer Spacer N spacer Spacer No spacer
Morning PEF, L/min
n 153 151 152 160 156 1 76 70
LS mean (SEM) 16.7 (3.9) 13.8 (3.7) 14.5 (3.8) 14.9 (3.5) 19.9 (3.9) 1 (3.7) 3.1 (5.4) 8.2 (5.1)
p-valuea <0.0001 0.0002 0.0002 <0.0001 <0.0001 < 0001 0.5631 0.1122
FEV1, L
n 139 131 141 140 135 1 64 60
LS mean (SEM) 0.123 (0.021) 0.122 (0.023) 0.123 (0.020) 0.121 (0.021) 0.110 (0.021) 0 2 (0.022) 0.040 (0.030) 0.036 (0.032)
p-valuea <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 < 0001 0.1730 0.2638
Asthma control, % of daysb
n 152 150 152 159 156 1 75 69
HL point estimate 47.42 43.03 44.37 45.79 45.83 4 1 34.54 29.70
p-valuec <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 < 0001 <0.0001 <0.0001
Asthma symptom score/day
n 153 151 152 160 156 1 76 70
HL point estimate 0.98 1.02 1.06 1.03 1.01  90 0.68 0.60
p-valuec <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 < 0001 0.0002 0.0009
Use of rescue medication, puffs/day
n 153 151 152 160 156 1 76 70
HL point estimate 0.79 1.00 1.00 1.00 1.07  86 0.80 0.50
p-valuec <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 < 0001 0.0001 0.0009
a Two-sided p-value (within-treatment differences) significance level 5% (based on analysis of covariance).
b Percentage of days with asthma control was based on use of rescue medication and asthma symptoms.
c Two-sided p-value (within-treatment differences) significance level 5% (based on Wilcoxon’s signed rank test, modification by tt).
CIC, ciclesonide; FEV1, forced expiratory volume in 1 s; HL, HodgeseLehmann; ITT, intent-to-treat; LS, least squares; PEF, peak exp tory
flow; SEM, standard error of the LS mean.
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1626 S. Pedersen et al.not influence the clinical effect or the risk of adverse
systemic effects of the treatment.
International guidelines recommend that the measure of
“asthma control” should reflect the extent to which the
manifestations of asthma have been reduced or removed by
treatment.19 In addition, rather than assessing a single
outcome, a combination of outcomes should be used as this
is more likely to be clinically relevant and show differences
between treatments.19 In line with this, the current study
used a multi-component definition for asthma control based
on a combination of the following variables: asthma
symptoms, use of rescue medication, morning PEF and PEF
fluctuation. However, when all four variables were
included, the percentage of asthma control days at base-
line was very low (in fact the median for all groups was
zero), indicating that this definition was perhaps too
stringent. With the more widely used definition, based on
asthma symptoms and rescue medication, the median
percentage of asthma control days at baseline increased to
approximately 15% and effect of treatment was also much
more pronounced, indicating that the PEF criteria used
markedly affected the results for asthma control. This is in
agreement with the findings in an earlier study with cicle-
sonide and fluticasone propionate using the same control
definitions in children with asthma. The proportions of
patients with asthma control post-treatment were approx-
imately 70e80% for the less stringent definition and
approximately 30e45% for the definition that included four
criteria.11 These figures are similar to those found in the
present study. As the duration of both studies was only 3
months and several outcomes require long periods of
treatment before the maximum effect is achieved,19 no
conclusions can be made about the proportion of patients
who will achieve control with continued treatment.
The criteria for the LOE endpoint were based on the
definitions of asthma control and early indications of loss of
control suggested in the various guidelines and papers on
asthma control,2,3,20,21 which suggest that increases in
symptoms, nocturnal awakenings and increases in the need
for rescue medication are early indications of loss of
control. Although our definitions of the LOE endpoints have
not been formally validated, the literature does suggest
that changes in the included parameters reflect changes in
asthma control.4,20,22
The magnitude of the placebo response for the asthma
control endpoint was relatively large. Significant placebo
responses have been reported in other studies in patients
with asthma, including children.23e25 The exact reason for
this is not known. Some regression towards the mean would
be expected to occur because all included patients must be
somewhat uncontrolled to be included in the study. In
addition, it has been shown that raising patients’ optimism
about treatment enhances the placebo effect for patient-
reported outcomes, but not lung function tests, whereas it
does not affect the response to active treatment for either
measure.26 In agreement with this the placebo response in
the present study was more pronounced for subjective than
objective outcomes.
Normally, the doseeresponse relationships for ICS are
rather shallow and most studies fail to demonstrate
significant doseeresponse effects.27e29 In agreement with
this, no significant doseeresponse was seen in the overallpopulation in our study. Such findings sometimes lead to the
erroneous conclusion that there will be no important clin-
ical benefit of increasing the dose of ICS. However, as
a significant doseeresponse was seen in the patients with
uncontrolled asthma at baseline, our data suggest that
many such patients would benefit from higher doses of ICS.
To the best of our knowledge, this is the first study to assess
the influence of the level of asthma control prior to treat-
ment on the likelihood of demonstrating significant dos-
eeresponse relationships.
The sample size for the current study was based, in part,
on the number of patients required to demonstrate a signifi-
cant treatment effect on LOE. However, in agreement with
clinical trial recommendations,20 the LOE criteria were
mainly designed to minimise the risk for the patients (a
placebo arm was included) rather than to assess efficacy.
This may have influenced the findings with LOE. Other
possible contributing factors to the finding could be that the
most common reason for LOE was nocturnal awakening,
regardless of cause (i.e. some may not have been due to
asthma) and the previously mentioned rather low morning
PEF values from the patients’ diaries, which were distinctly
lower than PEF values from spirometry at the clinic (data not
shown). This, in combination with the findings from a recent
study showing that morning PEF responds rather slowly to
treatment with montelukast or a fluticasoneesalmeterol
combination in children,30 may have contributed to the
relatively high rates of withdrawals due to LOE and lack of
differences between treatments in the study.
The statistically significant effects of ciclesonide on
other outcomes, including lung function (FEV1), asthma
symptom score and PAQLQ(S) were consistent with the
findings in other paediatric studies with ciclesonide.8e11
The low level of adverse local effects or systemic effect of
ciclesonide on the HPA-axis is in agreement with earlier
findings in children.8e11,31e33 Daily doses up to 320 mg have
been shown to not adversely affect on lower-leg growth or
urinary cortisol excretion8,31,33 and comparative studieswith
other ICS have found that mg for mg, ciclesonide causes
significantly less suppression of urinary cortisol excretion and
lower-leg growth rate than fluticasone propionate.31
In a previous study, it was found that treatment with
ciclesonide (in doses up to 160 mg per day) did not adversely
affect growth over 1 year.33 As ciclesonide did not signifi-
cantly improve lung function vs. placebo, it was suggested
that the lack of effect on growth could also have been due
to poor compliance, although canister weights and diary
recordings of medication intake suggested that this was not
the case.33e36 In contrast, the present study found signifi-
cant clinical effects, but still no adverse effect on stature
growth over 3 months. As earlier studies have consistently
reported that the effect of ICS is more marked at the
beginning of treatment5 and height in the current study was
measured by standardised stadiometry, we believe that any
clinically important differences in growth between treat-
ments would have been detected. In agreement with this,
an earlier study of 12 weeks’ duration found a significantly
higher growth rate with ciclesonide 160 mg/day (1.18 cm)
than with budesonide 400 mg/day (0.70 cm).9
A spacer device reduces oropharyngeal deposition of ICS
and the associated risk of local side effects. Many spacers
also increase drug deposition in the intrapulmonary airways
Ciclesonide for childhood asthma: The RAINBOW study 1627to some extent and spacers are generally easier to use than
a propellant MDI (pMDI) alone.2 As local adverse effects are
rare during ciclesonide treatment and its pMDI delivers
a high fraction of drug to the intrapulmonary airways, the
use of a spacer would not be expected to affect the clinical
or systemic effects to any significant extent in patients who
can use the pMDI correctly. In agreement with this, the use
of an AeroChamber Plus spacer in the current study did
not affect the efficacy or safety results. This finding
suggests that the two modes of administration can be used
interchangeably without adjustment of dose in children
with good inhalation technique. In addition, children with
a poor pMDI inhalation technique can start spacer treat-
ment with the usual recommended doses for the pMDI.
In conclusion, ciclesonide 40e160 mg once daily is an
effective and well-tolerated treatment for persistent
asthma in children aged 6e11 years. The efficacy and
safety of the treatment was not affected by use of a spacer.
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